| Elisigen is advancing global licensing discussions for its AAV gene therapy NG101 while preparing for a KOSDAQ IPO, leveraging its competitive pipeline to accelerate global commercialization. |
Read Original Article (Korean)
*Note: This link will redirect you to the original source in Korean.